PCRX - Pacira BioSciences Non-GAAP EPS of $0.51 misses by $0.34 revenue of $169.41M in-line
- Pacira BioSciences press release ( NASDAQ: PCRX ): Q2 Non-GAAP EPS of $0.51 misses by $0.34 .
- Revenue of $169.41M (+24.9% Y/Y) in-line.
-
The company is reiterating its FY2022 operating expense guidance as follows: Non-GAAP R&D expense of $75M to $85M and Non-GAAP SG&A expense of $220M to $230M.
For further details see:
Pacira BioSciences Non-GAAP EPS of $0.51 misses by $0.34, revenue of $169.41M in-line